keyboard_arrow_up

China Telmisartan Market Size, Competitive Landscape and Forecast to 2019

The number of hypertension patients in China is estimated to surpass 300 million with one in three adults suffering from it.

Out of all the dyazides, angiotension receptor blocker (ARB) is among a new generation which grows fast. Ever since the appearance of losartan which has been first applied in the clinic, 8 kinds of similar drugs have come out for sale and there are also 5 kinds of generic drugs in China. In recent years, telmisartan could be said as the fastest-growing kind of dyazide. View complete report at http://www.rnrmarketresearch.com/investigation-report-on-china-telmisartan-market-2010-2019-market-report.html .

Companies Mentioned

BoehringerIngelheim; China Resources Double Crane Pharmaceutical Co., Ltd; Yichang Changjiang Pharmaceutical Co., Ltd; Wanbang Biopharmaceuticals; Hainan Selection Pharmaceutical Co., Ltd

First developed by Boehringer-Ingelheim (Germany) and first marketed in the US in 1999 under the trade name of Micardis, telmisartan is an oral drug for the treatment of essential hypertension which should be taken once a day. It was marketed by Boehringer-Ingelheim under the trade name of Micardis and by Glaxo Wellcome plc under the trade name of Pritor in Germany in the same year. Telmisartan entered the Philippines in Dec. 1999 and Australia, Belgium, Britain in 2000. In 2013, its sales value surpassed USD 3 billion in the world. The patent of telmisartan expired in 2014.

The active pharmaceutical ingredients (APIs) and preparations of telmisartan were introduced by Boehringer-Ingelheim into China for sales at the end of 2000. After entering China, telmisartan grows fast with annual sales value rising from less than CNY 13 million in 2005 to CNY 200 million in 2014 and CAGR during this period reaching up to 35.8% despite a slight fall in 2014. Currently, telmisartan in the Chinese market mainly come from the following companies: Boehringer-Ingelheim (Germany), China Resources Double Crane Pharmaceutical Co., Ltd, Yichang Changjiang Pharmaceutical Co., Ltd, Wanbang Biopharmaceuticals and Hainan Selection Pharmaceutical Co., Ltd, among which Boehringer-Ingelheim (Germany) has the largest market share of over 80%, sales value in 2014 reaching up to CNY 167 million.

The market size of telmisartan in China is estimated to keep growing in the next few years.

Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=396963 .

Readers can get at least the following information from this report:

·    market size of telmisartan in China

·    competitive landscape of telmisartan in Chinese market

·    price of telmisartan made by different manufactures in China

·    market outlook of telmisartan in China

The author suggests the following groups of people purchase this report:

·    manufacturers of dyazide

·    investors/ research institutions interested in Chinese medicine market

·    any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1 Related Concepts of Telmisartan
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Telmisartan in China
2.1 Patent and Approval Status of Telmisartan in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Telmisartan in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Telmisartan in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Telmisartan in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Telmisartan in Chinese Hospitals in 2014
6.1 Boehringer-Ingelheim (Germany) (Trade Name: Micardis)
6.2 Beijing Wansheng Pharmaceutical Co., Ltd (Trade Name: Shu Ni Ya)
6.3 China Resources Double Crane Pharmaceutical Co., Ltd (Trade Name: Su He)
6.4 Yichang Changjiang Pharmaceutical Co., Ltd (Trade Name: Ou Mei Ning)
6.5 Wanbang Biopharmaceuticals (Trade Name: Bang Tan)
6.6 Hainan Selection Pharmaceutical Co., Ltd (Trade Name: Li Wen)
6.7 Dawnrays Pharmaceutical Limited (Trade Name: An Nei Qiang)

7 Major Manufacturers of Telmisartan in Chinese Market, 2010-2014
7.1 Boehringer-Ingelheim
7.2 China Resources Double Crane Pharmaceutical Co., Ltd
7.3 Yichang Changjiang Pharmaceutical Co., Ltd
7.4 Wanbang Biopharmaceuticals
7.5 Hainan Selection Pharmaceutical Co., Ltd

8 Market Outlook of Telmisartan in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Browse more report on “Hypertension Drugs” on http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/hypertension-drugs .